3-{[4-(3-Nitrophenyl)-1,3-thiazol-2-yl]amino}benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-{[4-(3-Nitrophenyl)-1,3-thiazol-2-yl]amino}benzoic acid
• 英文别名: 3-[[4-(3-nitrophenyl)-1,3-thiazol-2-yl]amino]benzoic acid
• 化学式: C16H11N3O4S
• 分子量: 341.3
• InChiKey: KYJUPOUIAXBNDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  136
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] 4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS<br/>[FR] DÉRIVÉS DE 4-PHÉNYL-N-(PHÉNYL)THIAZOL-2-AMINE ET COMPOSÉS ASSOCIÉS UTILISÉS COMME AGONISTES DU RÉCEPTEUR D'HYDROCARBURE ARYLE (AHR) POUR LE TRAITEMENT, PAR EX., DE TROUBLE LIÉS À L'ANGIOGENÈSE OU INFLAMMATOIRES
  申请人：IKENA ONCOLOGY INC

  公开号：WO2021127301A1

  公开（公告）日：2021-06-24

  4-phenyl-N-(phenyl)thiazol-2-amine and 4-(pyridin-3-yl)-N-( phenyl) thiazol-2-amine derivatives and the corresponding thiadiazole, thiophene, oxazole, oxadiazole, imidazole and triazole derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders.

  4-苯基-N-(苯基)噻唑-2-胺和4-(吡啶-3-基)-N-(苯基)噻唑-2-胺衍生物以及相应的噻二唑、噻吩、噁唑、噁二唑、咪唑和三唑衍生物和相关化合物作为芳香烃受体（AHR）激动剂，用于治疗涉及血管生成的疾病，例如视网膜病变、银屑病、类风湿性关节炎、肥胖和癌症，或炎症性疾病。
• Methods and pharmaceutical compositions for treating microbiome dysregulations associated with circadian clock disruption
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

  公开号：US11364219B2

  公开（公告）日：2022-06-21

  The present invention relates to the treatment of microbiome dysregulations. Said dysregulations may subsequently contribute to the development of several chronic diseases. Thus characterization of new post-biotic compounds inducing beneficial changes on host-microbiota interactions may be highly desirable. The inventors showed that Nlrp6 diurnally coordinates cyclical adaptation of the gut microbiota diversity to epithelial plasticity in response to a treatment with a Csnk2 inhibitor. The invention therefore relates to an inhibitor of Csnk2, for use in the treatment of microbiome dysregulations notably associated with circadian clock disruption. Said inhibitor may be selected among chemically synthesized or natural selective Csnk2 inhibitors such as flavones.

  本发明涉及微生物组失调的治疗。这些失调可能会导致多种慢性疾病的发生。因此，对能诱导宿主-微生物群相互作用发生有益变化的新生物后化合物进行表征可能是非常可取的。本发明者的研究表明，Nlrp6 在使用 Csnk2 抑制剂治疗的情况下，会周期性地协调肠道微生物群多样性对上皮可塑性的适应。因此，本发明涉及一种 Csnk2 抑制剂，用于治疗主要与昼夜节律紊乱有关的微生物组失调。所述抑制剂可选择化学合成或天然选择性 Csnk2 抑制剂，如黄酮类。
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING MICROBIOME DYSREGULATIONS ASSOCIATED WITH CIRCADIAN CLOCK DISRUPTION
  申请人：Institut National de la Santé et de la Recherche Médicale (INSERM)

  公开号：EP3458047B1

  公开（公告）日：2022-08-03
• Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway
  申请人：INSERM (Institut National de la Sante et de la Recherche Medicale)

  公开号：US20170051062A1

  公开（公告）日：2017-02-23

  The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.
• [EN] METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES MEDIATED BY THE NRP-1/OBR COMPLEX SIGNALING PATHWAY<br/>[FR] PROCÉDÉS ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE MALADIES INDUITES PAR LA VOIE DE SIGNALISATION DU COMPLEXE NRP-1/OBR
  申请人：INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE

  公开号：WO2015124588A1

  公开（公告）日：2015-08-27

  The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.